A nucleic acid-based electrochemical biosensor for the detection of influenza B virus from PCR samples using gold nanoparticle-adsorbed disposable graphite electrode and Meldola's blue as an intercalator

2011 ◽  
Vol 3 (7) ◽  
pp. 1607 ◽  
Author(s):  
Seyma Aydinlik ◽  
Dilsat Ozkan-Ariksoysal ◽  
Pinar Kara ◽  
A. Arzu Sayiner ◽  
Mehmet Ozsoz
2018 ◽  
Vol 56 (11) ◽  
Author(s):  
Dithi Banerjee ◽  
Neena Kanwar ◽  
Ferdaus Hassan ◽  
Cynthia Essmyer ◽  
Rangaraj Selvarangan

ABSTRACT The rapid and accurate detection of influenza A virus (FluA), influenza B virus (FluB), and respiratory syncytial virus (RSV) improves patient care. Sample-to-answer (STA) platforms based on nucleic acid amplification and detection of these viruses are simple, automated, and accurate. We compared six such platforms for the detection of FluA, FluB, and RSV: Cepheid GeneXpert Xpress Flu/RSV (Xpert), Hologic Panther Fusion Flu A/B/RSV (Fusion), Cobas influenza A/B & RSV (Liat), Luminex Aries Flu A/B & RSV (Aries), BioFire FilmArray respiratory panel (RP), and Diasorin Simplexa Flu A/B & RSV (Simplexa). Nasopharyngeal (NP) swab specimens (n = 225) from children previously tested by RP were assessed on these platforms. The results were compared to those of the Centers for Disease Control and Prevention (CDC)-developed real-time reverse transcription-PCR (rRT-PCR) assay for influenza A/B viruses and RSV. Subtyping for FluA and FluB was performed for discrepant analysis where applicable. The percent sensitivities/specificities for FluA detection were 100/100 (Fusion), 98.6/99.3 (Xpert), 100/100 (Liat), 98.6/100 (Aries), 98.6/100 (Simplexa), and 100/100 (RP). The percent sensitivities/specificities for FluB detection were 100/100 (Fusion), 97.9/99.4 (Xpert), 97.9/98.3 (Liat), 93.7/99.4 (Aries), 85.4/99.4 (Simplexa), and 95.8/97.7 (RP); and those for RSV detection were 98.1/99.4 (Xpert), 98.1/99.4 (Liat), 96.3/100 (Fusion), 94.4/100 (Aries), 87/94.4 (Simplexa), and 94.4/100 (RP). The 75 strains confirmed to be FluA included 29 pH1N1, 39 H3N2, 4 sH1N1, and 3 untyped strains. The 48 strains confirmed to be FluB included 33 strains of the Yamagata lineage, 13 of the Victoria lineage, 1 of both the Yamagata and Victoria lineages, and 1 of an unknown lineage. All six STA platforms demonstrated >95% sensitivity for FluA detection, while three platforms (Fusion, Xpert, and Liat) demonstrated >95% sensitivity for FluB and RSV detection.


2013 ◽  
Vol 19 (3) ◽  
pp. 511-512 ◽  
Author(s):  
Rogier Bodewes ◽  
Danny Morick ◽  
Gerrie de Mutsert ◽  
Nynke Osinga ◽  
Theo Bestebroer ◽  
...  

PLoS ONE ◽  
2015 ◽  
Vol 10 (1) ◽  
pp. e0116302 ◽  
Author(s):  
Nipaporn Tewawong ◽  
Kamol Suwannakarn ◽  
Slinporn Prachayangprecha ◽  
Sumeth Korkong ◽  
Preeyaporn Vichiwattana ◽  
...  

Vaccines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 800
Author(s):  
Jongsuk Mo ◽  
Stivalis Cardenas-Garcia ◽  
Jefferson J. S. Santos ◽  
Lucas M. Ferreri ◽  
C. Joaquín Cáceres ◽  
...  

Influenza B virus (IBV) is a major respiratory pathogen of humans, particularly in the elderly and children, and vaccines are the most effective way to control it. In previous work, incorporation of two mutations (E580G, S660A) along with the addition of an HA epitope tag in the PB1 segment of B/Brisbane/60/2008 (B/Bris) resulted in an attenuated strain that was safe and effective as a live attenuated vaccine. A third attempted mutation (K391E) in PB1 was not always stable. Interestingly, viruses that maintained the K391E mutation were associated with the mutation E48K. To explore the contribution of the E48K mutation to stability of the K391E mutation, a vaccine candidate was generated by inserting both mutations, along with attenuating mutations E580G and S660A, in PB1 of B/Bris (B/Bris PB1att 4M). Serial passages of the B/Bris PB1att 4M vaccine candidate in eggs and MDCK indicated high stability. In silico structural analysis revealed a potential interaction between amino acids at positions 48 and 391. In mice, B/Bris PB1att 4M was safe and provided complete protection against homologous challenge. These results confirm the compensatory effect of mutation E48K to stabilize the K391E mutation, resulting in a safer, yet still protective, IBV LAIV vaccine.


2006 ◽  
Vol 152 (2) ◽  
pp. 415-422 ◽  
Author(s):  
J.-M. Chen ◽  
Y.-J. Guo ◽  
K.-Y. Wu ◽  
J.-F. Guo ◽  
M. Wang ◽  
...  

Vaccine ◽  
2003 ◽  
Vol 21 (25-26) ◽  
pp. 3867-3874 ◽  
Author(s):  
G.M Vodeiko ◽  
J McInnis ◽  
V Chizhikov ◽  
R.A Levandowski

Virology ◽  
1984 ◽  
Vol 139 (1) ◽  
pp. 178-184 ◽  
Author(s):  
Michael W. Shaw ◽  
Purnell W. Choppin

2012 ◽  
Vol 205 (6) ◽  
pp. 895-905 ◽  
Author(s):  
Christopher D. Paddock ◽  
Lindy Liu ◽  
Amy M. Denison ◽  
Jeanine H. Bartlett ◽  
Robert C. Holman ◽  
...  

Author(s):  
Pınar YAZICI ÖZKAYA ◽  
Eşe Eda TURANLI ◽  
Hamdi METİN ◽  
Ayça Aydın UYSAL ◽  
Candan ÇİÇEK ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document